TSH Biopharm (8432) proudly announced its selection among the Top 5% of the 11th Corporate Governance Evaluation for OTC-listed Companies in Taiwan—an honor awarded to only 39 companies nationwide. This recognition highlights the company's outstanding performance in board governance, information transparency, and sustainability practices, reaffirming its excellence in governance as acknowledged by regulators and the market.

On the operational front, TSH Biopharm reported significant year-on-year growth in consolidated revenue, operating profit, and earnings per share (EPS) in 2024, reflecting a solid core business foundation. Growth was driven by the launch of new products and continued optimization of its product portfolio, contributing to sustained business momentum. Notably, Lonine, a treatment for rheumatoid arthritis and osteoarthritis, successfully entered the Macau market with its first shipment completed in late April—marking a strategic step forward in the company’s international expansion.

In recent years, TSH Biopharm has secured multiple key partnerships to expand its product portfolio into new therapeutic and diagnostic areas. Highlights include:

• Securing Taiwan marketing authorization for Tyrvaya, an innovative nasal spray for dry eye disease, with a full market launch planned within the year;

• Signing an exclusive agency agreement with a South Korean diagnostics company to introduce next-generation cancer screening solutions;

• Partnering with a Spanish pharmaceutical firm to acquire exclusive Taiwan distribution rights for a new orthopedic product.

Beyond corporate governance and business performance, TSH Biopharm remains deeply committed to corporate social responsibility. The company continues to lead impactful local and environmental initiatives, including the “Leopard Cat Rice” conservation project, now in its second year. In partnership with local farmers, the initiative protects the habitat of Taiwan’s endangered leopard cats. Simultaneously, through joint efforts with the Old Five Old Foundation, a charity sale of these products is held annually, with 100% of proceeds donated to support the Mobile Supply Van program—delivering essential goods and emotional support to elderly and mobility-impaired residents in remote communities across Taiwan. Since its inception, the program has served residents in nine cities and will further expand its service scope and volunteer engagement this year, establishing a model of sustainable corporate engagement in community care.

Looking ahead, TSH Biopharm will continue to strengthen its corporate governance framework, pursue a dual-growth strategy in operations and product development, and advance its ESG and philanthropic commitments. With a steady and forward-looking approach, the company remains dedicated to delivering both shareholder and societal value, advancing toward its goal of becoming a truly sustainable enterprise.